Tags

Type your tag names separated by a space and hit enter

Characterization and Chondroprotective Effects of Extracellular Vesicles From Plasma- and Serum-Based Autologous Blood-Derived Products for Osteoarthritis Therapy.
Front Bioeng Biotechnol. 2020; 8:584050.FB

Abstract

Autologous blood products gain increasing interest in the field of regenerative medicine as well as in orthopedics, aesthetic surgery, and cosmetics. Currently, citrate-anticoagulated platelet-rich plasma (CPRP) preparations are often applied in osteoarthritis (OA), but more physiological and cell-free alternatives such as hyperacute serum (hypACT) are under development. Besides growth factors, blood products also bring along extracellular vesicles (EVs) packed with signal molecules, which open up a new level of complexity at evaluating the functional spectrum of blood products. Large proportions of EVs originated from platelets in CPRP and hypACT, whereas very low erythrocyte and monocyte-derived EVs were detected via flow cytometry. EV treatment of chondrocytes enhanced the expression of anabolic markers type II collagen, SRY-box transcription factor 9 (SOX9), and aggrecan compared to full blood products, but also the catabolic marker and tissue remodeling factor matrix metalloproteinase 3, whereas hypACT EVs prevented type I collagen expression. CPRP blood product increased SOX9 protein expression, in contrast to hypACT blood product. However, hypACT EVs induced SOX9 protein expression while preventing interleukin-6 secretion. The results indicate that blood EVs are sufficient to induce chondrogenic gene expression changes in OA chondrocytes, while preventing proinflammatory cytokine release compared to full blood product. This highlights the potential of autologous blood-derived EVs as regulators of cartilage extracellular matrix metabolism and inflammation, as well as candidates for new cell-free therapeutic approaches for OA.

Authors+Show Affiliations

Center for Regenerative Medicine, Department for Health Sciences, Medicine and Research, Danube University Krems, Krems an der Donau, Austria.Center for Regenerative Medicine, Department for Health Sciences, Medicine and Research, Danube University Krems, Krems an der Donau, Austria.Center for Regenerative Medicine, Department for Health Sciences, Medicine and Research, Danube University Krems, Krems an der Donau, Austria. OrthoSera GmbH, Krems an der Donau, Austria.Center for Biomedical Technology, Department for Biomedical Research, Danube University Krems, Krems an der Donau, Austria.Center for Regenerative Medicine, Department for Health Sciences, Medicine and Research, Danube University Krems, Krems an der Donau, Austria.Deptartment Sports Physiology, University of Physical Education, Budapest, Hungary.Center for Biomedical Technology, Department for Biomedical Research, Danube University Krems, Krems an der Donau, Austria.Center for Regenerative Medicine, Department for Health Sciences, Medicine and Research, Danube University Krems, Krems an der Donau, Austria.Center for Regenerative Medicine, Department for Health Sciences, Medicine and Research, Danube University Krems, Krems an der Donau, Austria.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

33102466

Citation

Otahal, Alexander, et al. "Characterization and Chondroprotective Effects of Extracellular Vesicles From Plasma- and Serum-Based Autologous Blood-Derived Products for Osteoarthritis Therapy." Frontiers in Bioengineering and Biotechnology, vol. 8, 2020, p. 584050.
Otahal A, Kramer K, Kuten-Pella O, et al. Characterization and Chondroprotective Effects of Extracellular Vesicles From Plasma- and Serum-Based Autologous Blood-Derived Products for Osteoarthritis Therapy. Front Bioeng Biotechnol. 2020;8:584050.
Otahal, A., Kramer, K., Kuten-Pella, O., Weiss, R., Stotter, C., Lacza, Z., Weber, V., Nehrer, S., & De Luna, A. (2020). Characterization and Chondroprotective Effects of Extracellular Vesicles From Plasma- and Serum-Based Autologous Blood-Derived Products for Osteoarthritis Therapy. Frontiers in Bioengineering and Biotechnology, 8, 584050. https://doi.org/10.3389/fbioe.2020.584050
Otahal A, et al. Characterization and Chondroprotective Effects of Extracellular Vesicles From Plasma- and Serum-Based Autologous Blood-Derived Products for Osteoarthritis Therapy. Front Bioeng Biotechnol. 2020;8:584050. PubMed PMID: 33102466.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Characterization and Chondroprotective Effects of Extracellular Vesicles From Plasma- and Serum-Based Autologous Blood-Derived Products for Osteoarthritis Therapy. AU - Otahal,Alexander, AU - Kramer,Karina, AU - Kuten-Pella,Olga, AU - Weiss,René, AU - Stotter,Christoph, AU - Lacza,Zsombor, AU - Weber,Viktoria, AU - Nehrer,Stefan, AU - De Luna,Andrea, Y1 - 2020/09/25/ PY - 2020/07/16/received PY - 2020/08/31/accepted PY - 2020/10/26/entrez PY - 2020/10/27/pubmed PY - 2020/10/27/medline KW - autologous blood product KW - chondrocytes KW - exosomes KW - extracellular vesicles KW - gene expression KW - hyperacute serum KW - osteoarthritis KW - platelet rich plasma SP - 584050 EP - 584050 JF - Frontiers in bioengineering and biotechnology JO - Front Bioeng Biotechnol VL - 8 N2 - Autologous blood products gain increasing interest in the field of regenerative medicine as well as in orthopedics, aesthetic surgery, and cosmetics. Currently, citrate-anticoagulated platelet-rich plasma (CPRP) preparations are often applied in osteoarthritis (OA), but more physiological and cell-free alternatives such as hyperacute serum (hypACT) are under development. Besides growth factors, blood products also bring along extracellular vesicles (EVs) packed with signal molecules, which open up a new level of complexity at evaluating the functional spectrum of blood products. Large proportions of EVs originated from platelets in CPRP and hypACT, whereas very low erythrocyte and monocyte-derived EVs were detected via flow cytometry. EV treatment of chondrocytes enhanced the expression of anabolic markers type II collagen, SRY-box transcription factor 9 (SOX9), and aggrecan compared to full blood products, but also the catabolic marker and tissue remodeling factor matrix metalloproteinase 3, whereas hypACT EVs prevented type I collagen expression. CPRP blood product increased SOX9 protein expression, in contrast to hypACT blood product. However, hypACT EVs induced SOX9 protein expression while preventing interleukin-6 secretion. The results indicate that blood EVs are sufficient to induce chondrogenic gene expression changes in OA chondrocytes, while preventing proinflammatory cytokine release compared to full blood product. This highlights the potential of autologous blood-derived EVs as regulators of cartilage extracellular matrix metabolism and inflammation, as well as candidates for new cell-free therapeutic approaches for OA. SN - 2296-4185 UR - https://www.unboundmedicine.com/medline/citation/33102466/Characterization_and_Chondroprotective_Effects_of_Extracellular_Vesicles_From_Plasma-_and_Serum-Based_Autologous_Blood-Derived_Products_for_Osteoarthritis_Therapy L2 - https://doi.org/10.3389/fbioe.2020.584050 DB - PRIME DP - Unbound Medicine ER -
Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.